Preparation and biodistribution assessment of 111In-BPAMD as a novel agent for bone SPECT imaging

Radiochimica Acta

Volumn 103, Issue 9, 2015, Pages 653-661

  Yousefnia, Hassan ^a   Zolghadri, Samaneh ^a   Jalilian, Amir Reza ^a  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

Author keywords

bone metastases; BPAMD; In 111; SPECT

Indexed keywords

EID: 84940434460     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1515/ract-2015-2391     Document Type: Article

References (29)

1. IAEA-TECDOC-1549: Criteria for Palliation of Bone Metastases-Clinical Applications. International Atomic Energy Agency (IAEA), Austria, Vienna: IAEA (2007).
2. Lipton, A.: Pathophysiology of Bone Metastases: How This Knowledge May Lead to Therapeutic Intervention. J. Support. Oncol. 2, 205-220 (2004).
3. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., Thun, M.: Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36 (2001).
4. Rubens, R. D.: Bone metastases-the clinical problem. Eur. J. Cancer 34, 210-213 (1998).
5. 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl. Med. Biol. 39, 993-999 (2012).
6. Rybak, L. D., Rosenthal, D. I.: Radiological imaging for the diagnosis of bone metastases. Q. J. Nucl. Med. 45, 53-64 (2001).
7. Fellner, M., Baum, R. P., Kubícek, V., Hermann, P., Lukeš, I., Prasad, V. et al.: PET/CT imaging of osteoblastic bone metas-tases with 68Ga-bisphosphonates:frst human study. Eur. J. Nucl. Med. Mol. Imaging 37, 834 (2010).
8. 111In-Bombesin Conjugates for Prostate Cancer Imaging. J. Nucl. Med. 54, 1605-1612 (2013).
9. Lai, J., Quadri, S. M., Borchardt, P. E., Harris, L., Wucher, R., Askew, E. et al.: Pharmaco-kinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease. Clin. Cancer Res. 5, 3315-3323 (1999).
10. Nijhof, M. W., Oyen, W. J., Van Kampen, A., Claessens, R. A., Van der Meer, J. W., Corstens, F. H.: Evaluation of infections of the locomotor system with indium-111-labeled human IgG scintigraphy. J. Nucl. Med. 38, 1300-1305 (1997).
11. Balon, H. R., Goldsmith, S. J., Siegel, B. A., Silberstein, E. B., Donohoe, K. J., Krenning, E. P. et al: Society of Nuclear Medicine Procedure Guideline for Somatostatin Receptor Scintigraphy with In-111 Pentetreotide (2002).
12. Zettinig, G., Leitha, T., Niederle, B., Kaserer, K., Becherer, A., Kletter, K. et al.: FDG positron emission tomographic, radioio-dine, and MIBI imaging in a patient with poorly diferentiated insular thyroid carcinoma. Clin. Nucl. Med. 26, 599-601 (2001).
13. 111 In DOTMP for dosimetry of bone pain palliation agents. J. Ra-dioanal. Nucl. Chem. 304, 911-916 (2015).
14. 153Sm complexes: correlation with molecular modeling interaction studies. Nucl. Med. Biol. 29, 329-338 (2002).
15. IAEA-TECDOC-1401. Quantifying uncertainty in nuclear analytical measurements, Vienna, IAEA (2004).
16. United States Pharmacopoeia 28, NF 23, 1009 (2005).
17. United States Pharmacopoeia 28, NF 23, 1895 (2005).
18. Subramanian, G., McAfee, J. G., Blair, R. J.: Technetium-99m-methylene diphosphonate-a superior agent for skeletal imaging: Comparison with other technetium complexes. J. Nucl. Med. 16, 744-755 (1975).
19. 68Ga-labelled bisphosphonates for bone imaging in non-tumour models. Nucl. Med. Biol. 40, 823-830 (2013).
20. 99mTc-Methyl diphosphonate. In: Molecular imaging and contrast agent database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available at: http://www.ncbi.nlm.nih.gov/books/NBK24575.
21. Love, C., Din, A. S., Tomas, M. B., Kalapparambath, T. P., Pale-stro, C. J.: Radionuclide bone imaging: an illustrative review. Radiographics 23, 341-358 (2003).
22. Liu, W., Hajibeigi, A., Lin, M., Rostollan, C. L., Kovacs, Z., Öz, O. K., Sun, X.: An osteoclast-targeting agent for imaging and therapy of bone metastasis. Bioorg. Med. Chem. Lett. 18, 4789-4793 (2008).
23. 99mTc-labelled bisphospho-nates as superior bone imaging agents. Molecules 16, 6165-6178 (2011).
24. 99mTc-labeled probes for targeting osteogenic bone region. Bioconjugate Chem. 24, 1248-1255 (2013).
25. 166Ho-BPAMD as a potential therapeutic bone-seeking agent. J. Ra-dioanal. Nucl. Chem. (2015), DOI 10.1007/s10967-014-3924-1.
26. Baum, R. P., Kulkarni, H. R.: Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-The Bad Berka experience. Theranostics 2, 437-447 (2012).
27. Bushberg, J. T., Seibert, J. A., Leidholdt, E. M., Boone, J. M.: The Essential Physics of Medical Imaging, Third Edition, Lippincott Williams & Wilkins (2011).
28. Muller, C., Schibli, R.: Single Photon Emission Computed Tomography Tracer. Mol. Imaging Oncol. 187, 65-105 (2013).
29. 99mTc-labeled probes for targeting osteogenic bone region. Bioconjug. Chem. 24, 1248-1255 (2013).